Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene Expression Signature of Microcalcification among Taiwanese Breast Cancer

ABSTRACT: Gene Expression Signature of Microcalcification among Taiwanese Breast Cancer

PROVIDER: PRJNA610873 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene Expression Signature of Microcalcification among Taiwanese Breast Cancer

Project description:Microcalcification is one of the most common radiological and pathological features of breast ductal carcinoma in situ (DCIS), and to a lesser extent, invasive ductal carcinoma. We evaluated transcriptional profiles associated with ectopic mammary mineralization. We evaluated the transcriptional profiles associated with breast cancer microcalcification for Taiwanese breast cancer and a gene expression signature was derived.

2020-10-05 | GSE146558 | GEO

Molecular subtyping of Triple negative Breast Cancer from Taiwanese

Project description:'Precision medicine' is a concept that by utilizing modern molecular diagnostics, an effective therapy is accurately applied for each cancer patient to improve their survival rates. The aim of this study was to compare the molecular subtypes of triple negative breast cancer (TNBC) between Taiwanese and other datasets.

2017-06-13 | GSE95700 | GEO

Identification of Prognostic Genes for Recurrent Risk Prediction in Triple Negative Breast Cancer Patients in Taiwan

Project description:Discrepancies in the prognosis of triple negative breast cancer exist between Caucasian and Asian populations. Yet, the gene signature of triple negative breast cancer specifically for Asians has not become available. Therefore, the purpose of this study is to construct a prediction model for recurrence of triple negative breast cancer in Taiwanese patients.

2012-02-02 | GSE33095 | GEO

A consensus hypoxia signature in breast cancer

Project description:A consensus hypoxia signature in breast cancer

| PRJNA437670 | ENA

Concordance of PAM50 molecular subtyping between oligonucleotide microarray and NanoString nCounter assay for Taiwanese breast cancer

Project description:Five molecular subtypes have been identified according to intrinsic genes transcription. Microarrays have been adopted for molecular subtyping in addition to the original NanoString nCounter assay. This study aimed to evaluate subtyping consistency among Taiwanese breast cancers. Our study showed that fundamental discrepancy exists between distinct gene expression measuring approaches, and cross platform equivalence should not be overemphasized with too much extrapolation.

2021-09-01 | GSE162228 | GEO

ABI1-based 7-gene expression signature predicts breast cancer metastasis and survival

Project description:Collection of human breast cancer gene expressed measured by GPL2567. This subpopulation of breast cancer has gene expression and clinical data which were used for survival prediction analysis; resulting in emphasizing the ABI1-based 7-gene prognostic signature, as a prospective multi-gene expression clinical biomarker of breast cancer aggressiveness and metastasis, and therapeutic target.

2021-08-18 | GSE159956 | GEO

A six-gene signature predicting breast cancer lung metastasis

Project description:The lungs are a frequent target of metastatic breast cancer cells, but the underlying molecular mechanisms are unclear. All existing data were obtained either using statistical association between gene expression measurements found in primary tumors and clinical outcome, or using experimentally derived signatures from mouse tumor models. Here, we describe a distinct approach that consists to utilize tissue surgically resected from lung metastatic lesions and compare their gene expression profiles with those from non-pulmonary sites, all coming from breast cancer patients. We demonstrate that the gene expression profiles of organ-specific metastatic lesions can be used to predict lung metastasis in breast cancer. We identified a set of 21 lung metastasis-associated genes. Using a cohort of 72 lymph node-negative breast cancer patients, we developed a six-gene prognostic classifier that discriminated breast primary cancers with a significantly higher risk of lung metastasis. We then validated the predictive ability of the six-gene signature in 3 independent cohorts of breast cancers consisting of a total of 721 patients. Finally, we demonstrated that the signature improves risk stratification independently of known standard clinical parameters and a previously established lung metastasis signature based on an experimental breast cancer metastasis model. Keywords: Disease state analysis

2008-08-15 | GSE11078 | GEO

ABI1-based 7-gene expression signature predicts breast cancer metastasis and survival

Project description:ABI1-based 7-gene expression signature predicts breast cancer metastasis and survival

| PRJNA670946 | ENA

Multi-center validation of a gene expression based prognostic signature in lymph node-negative primary breast cancer.

Project description:A gene signature predicting survival of breast cancer patients was validated on a custom chip. Keywords: breast cancer patient survival analysis

2005-10-15 | GSE3453 | GEO

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

Project description:Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS: We compared the gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed genes were used to generate a 186-gene invasiveness gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS: There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) signature. CONCLUSIONS: The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This genetic signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR signature in breast cancer. Keywords: cell type comparison

2007-03-10 | GSE6883 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data